Michael Hogue, MD
Ophthalmology · Edmond, OKNPI 1902895600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 207 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$996
- Alcon$875
- Bausch & Lomb, A Division Of Bausch Health US, LLC$656
- Bausch & Lomb Americas Inc.$589
- Sun Pharmaceutical Industries Inc.$570
- Aerie Pharmaceuticals, Inc.$322
- plus $2K from 13 others
What the payments were for
- Speaking & faculty fees$130%
- Food & beverage$5,46599%
- Entertainment$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $996 |
| Alcon | 36 | $875 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $656 |
| Bausch & Lomb Americas Inc. | 14 | $589 |
| Sun Pharmaceutical Industries Inc. | 13 | $570 |
| Aerie Pharmaceuticals, Inc. | 6 | $322 |
| Glaukos Corporation | 6 | $282 |
| Oyster Point Pharma, Inc. | 8 | $215 |
| Harrow Eye, LLC | 6 | $210 |
| Dompe US, Inc. | 4 | $205 |
| Eyevance Pharmaceuticals LLC | 3 | $180 |
| Tarsus Pharmaceuticals, Inc. | 12 | $152 |
| Ocular Therapeutix, Inc. | 4 | $94 |
| Novartis | 3 | $44 |
| Optos, Inc. | 1 | $35 |
| Tearlab Corp | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Sight Sciences, Inc. | 1 | $17 |
| Rxsight Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$466
- Rocklatan$243
- Rhopressa$243
- iStent Trabecular Micro-Bypass Stent System$144
- iStent infinite Trabecular Micro-Bypass System Model iS3$144
- iStent Inject Trabecular Micro-Bypass System$144
- Flarex$132
- MIEBO$124
- XIIDRA$124
- Clareon PanOptix Pro$123
- Oxervate$123
- PanOptix$122
- DURYSTA$115
- ENVISTA TORIC$107
- VYZULTA$107
- Clareon$106
How this compares
$5,512 in reported general payments places this provider in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 110 | $46,421 |
| RestasisCyclosporine | 23 | $38,521 |
| RocklatanNetarsudil Mesylat/Latanoprost | 43 | $22,367 |
| CombiganBrimonidine Tartrate/Timolol | 54 | $15,454 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $6,905 |
| VyzultaLatanoprostene Bunod | 14 | $5,541 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,699 |
| Latanoprost | 210 | $2,415 |
| Travoprost | 16 | $2,111 |
| TafluprostTafluprost/Pf | 12 | $1,998 |
| Timolol Maleate | 102 | $1,370 |
| Brimonidine Tartrate | 41 | $1,071 |
| Prednisolone Acetate | 21 | $846 |
| Ketorolac Tromethamine | 16 | $653 |
| Doxycycline Monohydrate | 14 | $404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $996 | $100,396187 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $322 | $22,36743 claims |
| AlconSimbrinza | $875 | $6,90525 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $589 | $5,54114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Edmond
- Don NguyenEdmond$36K
- Bradley BrittonEdmond$25K
- Jeffrey ShaverEdmond$11K
- Whitney PotterEdmond$10K
- Vincent VenincasaEdmond$5K
- Jared JacksonEdmond$3K
- Brian MorganEdmond$3K
- Ronald RebenitschOklahoma City$141K
- Kyle RogersEnid$19K
- Edward JonesOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.